Suppr超能文献

光动力疗法对脉络膜血管指数与脉络膜厚度的长期影响作为慢性中心性浆液性脉络膜视网膜病变的生物标志物

Long-term effect of photodynamic therapy on choroidal vascularity index versus choroidal thickness as biomarkers for chronic central serous chorioretinopathy.

作者信息

Bui Patricia T A, Stattin Martin, Ahmed-Balestra Daniel, Kickinger Stefan, Krepler Katharina, Ansari-Shahrezaei Siamak

机构信息

Karl Landsteiner Institute for Retinal Research and Imaging, Vienna, Austria.

Vienna Health Care Group Clinic Landstraße, Department of Ophthalmology and Optometry, Vienna, Austria.

出版信息

Eye (Lond). 2025 Apr;39(6):1183-1192. doi: 10.1038/s41433-024-03571-7. Epub 2025 Jan 6.

Abstract

OBJECTIVE

To investigate the long-term impact of half-fluence photodynamic therapy (PDT) on chorioretinal architecture in chronic central serous chorioretinopathy (cCSCR) through novel choroidal vascularity index (CVI) versus previously established subfoveal choroidal thickness (SFCT).

METHODS

This post-hoc analysis included prospectively collected swept-source optical coherence tomography (SS-OCT) images of a total of 29 cCSCR and fellow eyes (FE), acquired before, one and 12 months after PDT. CVI, total choroidal area (TCA), luminal area (LA) and stromal area (SA) were calculated using validated binarization technique. Central macular thickness (CMT), SFCT and subretinal fluid (SRF) were assessed. Longitudinal changes following PDT and associations between all parameters were investigated.

RESULTS

CVI, TCA, LA, SFCT and CMT significantly decreased at month 1 (all p < 0.001). From month 1 to 12, CVI (p < 0.001) and LA (p = 0.01) increased but remained significantly lower than at baseline (p = 0.001 and p < 0.001). SFCT and CMT remained stable (all p = 1.0). SA and all FE parameters showed no significant changes at any time point. Comparing affected and FE, there were significant CVI differences at baseline (p < 0.001), month 1 (p = 0.01) and 12 (p < 0.001). SRF was significantly associated with higher CVI (p < 0.001), LA (p = 0.031), SFCT (p = 0.038).

CONCLUSION

Half-fluence PDT significantly affects choroidal architecture, with sustained CVI and SFCT reductions 12 months post-treatment. Use of CVI as both a treatment response and disease activity marker is merited. There is a large discrepancy between CVI and SFCT, suggesting they each represent different anatomic responses. CVI proves to be a more specific and reliable CSCR biomarker than previously established SFCT.

摘要

目的

通过新型脉络膜血管指数(CVI)与先前确立的中心凹下脉络膜厚度(SFCT),研究半剂量光动力疗法(PDT)对慢性中心性浆液性脉络膜视网膜病变(cCSCR)脉络膜视网膜结构的长期影响。

方法

这项事后分析纳入了前瞻性收集的共29例cCSCR患者及其对侧眼(FE)的扫频源光学相干断层扫描(SS-OCT)图像,这些图像在PDT治疗前、治疗后1个月和12个月获取。使用经过验证的二值化技术计算CVI、脉络膜总面积(TCA)、管腔面积(LA)和基质面积(SA)。评估中心黄斑厚度(CMT)、SFCT和视网膜下液(SRF)。研究PDT后的纵向变化以及所有参数之间的关联。

结果

在第1个月时,CVI、TCA、LA、SFCT和CMT均显著降低(所有p<0.001)。从第1个月到第12个月,CVI(p<0.001)和LA(p=0.01)有所增加,但仍显著低于基线水平(p=0.001和p<0.001)。SFCT和CMT保持稳定(所有p=1.0)。SA和所有FE参数在任何时间点均无显著变化。比较患眼和FE,在基线(p<0.001)、第1个月(p=0.01)和第12个月(p<0.001)时CVI存在显著差异。SRF与较高的CVI(p<0.001)、LA(p=0.031)、SFCT(p=0.038)显著相关。

结论

半剂量PDT显著影响脉络膜结构,治疗后12个月CVI和SFCT持续降低。将CVI用作治疗反应和疾病活动标志物是有价值的。CVI和SFCT之间存在较大差异,表明它们各自代表不同的解剖学反应。事实证明,CVI是一种比先前确立的SFCT更特异、更可靠的CSCR生物标志物。

相似文献

2
Choroidal Anatomic Alterations After Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Multicenter Study.
Am J Ophthalmol. 2020 Sep;217:104-113. doi: 10.1016/j.ajo.2020.04.022. Epub 2020 Apr 28.
3
Visual and anatomical evaluation of navigated subthreshold micropulse laser versus photodynamic therapy in managing chronic central serous chorioretinopathy.
Graefes Arch Clin Exp Ophthalmol. 2025 Feb;263(2):405-414. doi: 10.1007/s00417-024-06666-9. Epub 2024 Oct 19.
5
Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.
Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2155-2161. doi: 10.1007/s00417-019-04426-8. Epub 2019 Jul 31.
6
Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
Ophthalmologica. 2019;241(2):105-115. doi: 10.1159/000490773. Epub 2018 Aug 15.
7
Interventions for central serous chorioretinopathy: a network meta-analysis.
Cochrane Database Syst Rev. 2015 Dec 22;2015(12):CD011841. doi: 10.1002/14651858.CD011841.pub2.
9
Interventions for central serous chorioretinopathy: a network meta-analysis.
Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.

引用本文的文献

本文引用的文献

1
2
Choroidal vascularity index as an activity criterion and a treatment response measure in chronic central serous chorioretinopathy.
Ophthalmic Physiol Opt. 2023 Sep;43(5):1203-1210. doi: 10.1111/opo.13187. Epub 2023 Jun 15.
3
Choroidal Vascularity Index versus Choroidal Thickness as Biomarkers of Acute Central Serous Chorioretinopathy.
Ophthalmic Res. 2023;66(1):627-635. doi: 10.1159/000529474. Epub 2023 Feb 28.
4
The Choroid after Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
Acta Medica (Hradec Kralove). 2022;65(3):89-98. doi: 10.14712/18059694.2022.24.
6
7
Choroidal vascularity index: a step towards software as a medical device.
Br J Ophthalmol. 2022 Feb;106(2):149-155. doi: 10.1136/bjophthalmol-2021-318782. Epub 2021 Jan 29.
8
Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.
Photodiagnosis Photodyn Ther. 2021 Mar;33:102081. doi: 10.1016/j.pdpdt.2020.102081. Epub 2020 Nov 3.
9
Choroidal Anatomic Alterations After Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Multicenter Study.
Am J Ophthalmol. 2020 Sep;217:104-113. doi: 10.1016/j.ajo.2020.04.022. Epub 2020 Apr 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验